Viking Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Viking Therapeutics
VKTX Stock  USD 33.69  0.26  0.78%   
Viking Therapeutics financial statements provide useful quarterly and yearly information to potential Viking Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Viking Therapeutics financial statements helps investors assess Viking Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Viking Therapeutics' valuation are summarized below:
Market Capitalization
3.8 B
Earnings Share
(0.94)
We have found one hundred twenty available fundamental trend indicators for Viking Therapeutics, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Viking Therapeutics current market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 386.2 M in 2025, whereas Enterprise Value is likely to drop slightly above 174.7 M in 2025.
Check Viking Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viking Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 319 K, Interest Expense of 75.2 K or Selling General Administrative of 44.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.76. Viking financial statements analysis is a perfect complement when working with Viking Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Viking Therapeutics Correlation against competitors.
For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide.

Viking Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Short and Long Term Debt Total1.5 M1.4 M1.1 M
Pretty Stable
Other Current Liabilities13.6 M13 M4.8 M
Slightly volatile
Total Current Liabilities23.1 M22 M9.9 M
Slightly volatile
Accounts Payable9.1 M8.6 M3 M
Slightly volatile
Common Stock Total Equity5831.1 K541
Slightly volatile
Non Current Liabilities Total1.1 M842.4 K1.2 M
Very volatile
Other Stockholder Equity877.6 M835.8 M296.3 M
Slightly volatile
Total Liabilities24.2 M23.1 M10.7 M
Slightly volatile
Common Stock6261.1 K544
Slightly volatile
Total Assets445 M423.8 M157.2 M
Slightly volatile
Other Liabilities10.3 K10.8 K274.1 K
Pretty Stable
Cash67 M63.8 M20.4 M
Slightly volatile
Non Current Assets Total755.8 K1.5 M610.7 K
Slightly volatile
Non Currrent Assets Other118.8 K125.1 K269.8 K
Pretty Stable
Cash And Short Term Investments437.2 M416.4 M153 M
Slightly volatile
Common Stock Shares Outstanding113.9 M108.5 M46.4 M
Slightly volatile
Liabilities And Stockholders Equity445 M423.8 M157.2 M
Slightly volatile
Total Current Assets443.4 M422.3 M156.5 M
Slightly volatile
Short Term Debt277 K291.6 K761.6 K
Very volatile
Other Assets60.7 K63.9 K845.2 K
Slightly volatile
Other Current Assets4.9 M5.9 M3.5 M
Slightly volatile
Deferred Long Term Liabilities32.5 K34.2 K754.2 K
Slightly volatile
Short and Long Term Debt2.5 M4 M2.3 M
Slightly volatile
Short Term Investments370.2 M352.5 M136.8 M
Slightly volatile
Long Term Debt Total1.7 M1.9 M2.1 M
Slightly volatile
Capital Surpluse317.3 M512.1 M240.8 M
Slightly volatile
Additional Paid In Capital62.8 M108.5 M59.5 M
Slightly volatile
Non Current Liabilities Other789.5 K1.1 M1.4 M
Slightly volatile
Net Invested Capital240.7 M400.7 M143.2 M
Slightly volatile
Net Working Capital239.9 M400.3 M141.2 M
Slightly volatile
Capital Stock800900981
Slightly volatile
Property Plant And Equipment Net767.4 K1.3 M683.3 K
Slightly volatile
Capital Lease Obligations852.3 K1.4 M758.3 K
Slightly volatile
Property Plant And Equipment Gross767.4 K1.3 M683.3 K
Slightly volatile

Viking Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense75.2 K79.2 K450.4 K
Very volatile
Selling General Administrative44.7 M42.6 M12.2 M
Slightly volatile
Other Operating Expenses121.7 M116 M39.7 M
Slightly volatile
Research Development77 M73.4 M27.5 M
Slightly volatile
Total Operating Expenses121.7 M116 M39.7 M
Slightly volatile
Interest Income13.3 M12.7 M3.8 M
Slightly volatile
Reconciled Depreciation311.1 K333.5 K274.9 K
Slightly volatile
Selling And Marketing Expenses233.6 K262.8 K286.5 K
Slightly volatile

Viking Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation20.2 M19.3 M5.6 M
Slightly volatile
Total Cash From Financing Activities327.7 M312.1 M80.1 M
Slightly volatile
End Period Cash Flow67 M63.8 M20.4 M
Slightly volatile
Begin Period Cash Flow44.2 M42.1 M14.1 M
Slightly volatile
Depreciation249.7 K262.8 K596.2 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Average Payables761.9 K857.2 K934.5 K
Slightly volatile
Payables Turnover0.04250.04470.094
Slightly volatile
Cash Per Share1.823.451.8999
Slightly volatile
Days Payables Outstanding10.1 K9.6 K5.1 K
Slightly volatile
Income Quality0.510.770.6165
Slightly volatile
Current Ratio14.117.2714.3468
Slightly volatile
Graham Number9.4310.010.3774
Slightly volatile
Interest Debt Per Share0.01560.01645.5124
Slightly volatile
Debt To Assets0.00370.00390.4527
Slightly volatile
Days Of Payables Outstanding10.1 K9.6 K5.1 K
Slightly volatile
Ebt Per Ebit1.180.981.0655
Pretty Stable
Quick Ratio14.117.2714.3468
Slightly volatile
Net Income Per E B T0.770.880.9144
Pretty Stable
Cash Ratio1.462.611.7686
Slightly volatile
Debt Ratio0.00370.00390.4527
Slightly volatile

Viking Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap386.2 M367.8 M237.4 M
Slightly volatile
Enterprise Value174.7 M342 M214.6 M
Slightly volatile

Viking Fundamental Market Drivers

Cash And Short Term Investments362.1 M

Viking Upcoming Events

14th of February 2024
Upcoming Quarterly Report
View
24th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Viking Therapeutics Financial Statements

Viking Therapeutics investors use historical fundamental indicators, such as Viking Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Viking Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-10.5 M-9.9 M
Cost Of Revenue335.8 K352.6 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FFord Motor
GMGeneral Motors
SSentinelOne

Additional Tools for Viking Stock Analysis

When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY